The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prospective assessment of circulating endothelial cells (CECs) as early markers of clear cell renal cell carcinoma (CCRCC) progression in first-line setting: The Circles study (SOGUG 2011-01).
Victor Oyarvides
No relevant relationships to disclose
Daniel Castellano
Consultant or Advisory Role - GlaxoSmithKline; Pfizer
Research Funding - Novartis
Luis Leon Mateos
No relevant relationships to disclose
Emilio Esteban
No relevant relationships to disclose
Laura Basterretxea
No relevant relationships to disclose
Aranzazu Gonzalez del Alba
No relevant relationships to disclose
Jose Angel Arranz Arija
No relevant relationships to disclose
Maria Jose Mendez
No relevant relationships to disclose
Francisco Javier Garcia Del Muro
No relevant relationships to disclose
Miguel Angel Climent
No relevant relationships to disclose
Juan Antonio Virizuela
No relevant relationships to disclose
Susana Hernando POLO
No relevant relationships to disclose
Jesus Garcia-Donas
Consultant or Advisory Role - GlaxoSmithKline; Novartis; Pfizer
Honoraria - GlaxoSmithKline; Novartis; Pfizer
Research Funding - Pfizer; Pfizer